🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 100% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Softgel(s) Serving Size
30 Servings
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

180 mcg
✅ 1.5× RDA — within safe limits 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.18mg

Other Ingredients

Medium Chain Triglycerides Gelatin Glycerin Olive Oil Water, Purified

Label Claims — Verification

All Other
Structure/Function
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free

Product Information

📋 Directions for Use

Suggested Use: Take 1 softgel daily.

⚠️ Warnings & Precautions

Precautions: Consult a health care practitioner before use if you take warfarin or other blood thinning products, or are pregnant or nursing, have a serious medical condition, or use any medications.

Keep out of reach of children.

🧪 Formulation Notes

MK-7 is menaquinone-7, also known as vitamin K2.

Unconditionally guaranteed for purity and labeled potency.

Clinical Grade

Bone support Supports ultimate calcium utilization

GF Gluten free

Additional Information

Almost out? Call 1-866-599-9491

Store bottle in a cool, dry place.

Product Details

UPC / SKU 8 10047 39031 2
DSLD Entry Date 2022-06-16
Product Type Vitamin
Form Softgel Capsule
DSLD ID 267456
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →